BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seed CR, Kiely P, Hoad VC, Keller AJ. Refining the risk estimate for transfusion-transmission of occult hepatitis B virus. Vox Sang 2017;112:3-8. [PMID: 27564651 DOI: 10.1111/vox.12446] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Seed CR. Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening apply. VOXS 2018;13:70-5. [DOI: 10.1111/voxs.12368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Grubyte S, Urboniene J, Nedzinskiene L, Jelinskaite A, Zagminas K, Ambrozaitis A, Jancoriene L. Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study. PLoS One 2021;16:e0246704. [PMID: 33606700 DOI: 10.1371/journal.pone.0246704] [Reference Citation Analysis]
3 Candotti D, Laperche S. Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures? Front Med (Lausanne) 2018;5:29. [PMID: 29515997 DOI: 10.3389/fmed.2018.00029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
4 Custer B. Health Economics in Blood Safety. In: Shan H, Dodd RY, editors. Blood Safety. Cham: Springer International Publishing; 2019. pp. 53-81. [DOI: 10.1007/978-3-319-94436-4_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lelie N, Busch M, Kleinman S. Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components: A review of observed versus modeled infectivity from donors with window period and occult HBV infections. Transfusion 2021;61:3190-201. [PMID: 34590320 DOI: 10.1111/trf.16675] [Reference Citation Analysis]
6 Harvala H, Reynolds C, Gibney Z, Derrick J, Ijaz S, Davison KL, Brailsford S. Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety? Transfusion 2021;61:2402-13. [PMID: 34114670 DOI: 10.1111/trf.16543] [Reference Citation Analysis]
7 Zhong Y, Liu DL, Ahmed MMM, Li PH, Zhou XL, Xie QD, Xu XQ, Han TT, Hou ZW, Zhong CY, Huang JH, Zeng F, Huang TH. Host genes regulate transcription of sperm-introduced hepatitis B virus genes in embryo. Reprod Toxicol 2017;73:158-66. [PMID: 28822827 DOI: 10.1016/j.reprotox.2017.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Seed CR, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, Kwon SY, Oh EY, Kim JN, Chua SS, Lam S, Ang AL, Tsoi WC, Hewitt PE, Davison K, Tettmar K, O'Flaherty N, Boland F, Williams P, Pomeroy L, Wendel S, Fachini R, Scuracchio PSP, Carminato P, Fearon M, O'Brien SF, Delages G, Kiely P, Hoad VC, Matsubayashi K, Satake M, Taira R, Stramer SL, Sauleda S, Bes M, Piron M, Ekiaby ME, Vermeulen M, Stezinar SL, Nograšek P, Jarvis LM, Petrik J, Charlewood R, Flanagan P, Grabarczyk P, Kopacz A, Łętowska M, Schmidt M, Seifried E. International forum on Occult hepatitis B infection and transfusion safety. Vox Sang 2019;114:397-406. [PMID: 30818422 DOI: 10.1111/vox.12744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Seed CR, Allain J, Lozano M, Laperche S, Gallian P, Gross S, Kwon S, Oh E, Kim J, Chua SS, Lam S, Ang AL, Tsoi W, Hewitt PE, Davison KL, Tettmar K, O'flaherty N, Boland F, Williams P, Pomeroy L, Wendel S, Fachini R, Scuracchio P, Carminato P, Fearon M, O'brien SF, Delage G, Kiely P, Hoad V, Matsubayashi K, Satake M, Taira R, Stramer SL, Sauleda S, Bes M, Piron M, El Ekiaby M, Vermeulen M, Levičnik Stezinar S, Nograšek P, Jarvis LM, Petrik J, Charlewood R, Flanagan P, Grabarczyk P, Kopacz A, Łętowska M, Seifried E, Schmidt M. International Forum on Occult hepatitis B infection and transfusion safety. Vox Sang 2019;114:e1-e35. [DOI: 10.1111/vox.12743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Weusten J, van Drimmelen H, Vermeulen M, Lelie N. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios: RISK MODEL FOR TRANSMISSION OF OBI. Transfusion 2017;57:841-9. [DOI: 10.1111/trf.14050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
11 López-Menchero C, Alvarez M, Fernández P, Guzmán M, Ortiz-de-Salazar MI, Arbona C. Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017). Blood Transfus 2019;17:418-27. [PMID: 31403928 DOI: 10.2450/2019.0058-19] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Velati C, Romanò L, Pati I, Marano G, Piccinini V, Catalano L, Pupella S, Vaglio S, Veropalumbo E, Masiello F, Pisani G, Grazzini G, Zanetti A, Liumbruno GM. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018. Blood Transfus 2019;17:409-17. [PMID: 31846606 DOI: 10.2450/2019.0245-19] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 van de Laar TJ, Hogema BM, Molenaar-de Backer MW, Marijt-van der Kreek T, Zaaijer HL. Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing. Transfusion 2021;61:2116-24. [PMID: 33899233 DOI: 10.1111/trf.16420] [Reference Citation Analysis]